A major step forward for patients living with Metabolic Dysfunction-Associated Steatohepatitis (MASH) across the Middle East and North Africa (MENA)

Date: March 30, 2026

 
On March 30, 2026, NewBridge Pharmaceuticals and Madrigal Pharmaceuticals entered into a distribution agreement for the MENA region, reinforcing a shared commitment to improving access to innovative therapies for patients living with serious liver disease.
 

“We are proud to partner with Madrigal Pharmaceuticals to help expand access to innovative treatment options for patients across the MENA region,” said Joe Henein, President & CEO of NewBridge Pharmaceuticals. “This agreement reflects NewBridge’s commitment to addressing significant unmet medical needs and strengthening our leadership in specialty and innovative medicines.”
 
MASH is a serious and progressive liver disease that can lead to advanced liver fibrosis, cirrhosis, liver failure, liver cancer, and the need for liver transplantation if left untreated. As the burden of liver disease continues to grow globally and across the region, timely diagnosis and access to appropriate care have never been more important.
 
Link: https://www.linkedin.com/feed/update/urn:li:activity:7469988737410588672